本次活动由四川省药品监督管理局、成都东部新区管委会联合主办，以"临床驱动，生态赋能，共筑医 疗器械创新转化新高地"为主题，汇聚近200位政、医、学、研、产领域嘉宾，共同搭建高效对接桥梁， 推动一批具有临床价值的创新医疗（002173）器械项目加速落地，标志着川渝地区在构建"临床需求— 研发创新—产业落地—政策支持—金融助力"五位一体的医疗器械创新生态体系上迈出了坚实一步。 活动现场 图片来源：成都东部新区提供 1月31日，医疗器械领先用户社区应用示范暨"春雨行动"临床研究成果转化对接会在成都东部新区未来 医学城举行。 作为成都东部新区生物医药产业发展高地，成都未来医学城以临床医疗应用为创新原点，构建起"医教 研产"一体化创新发展体系，致力于打造一座未来医学创新与探索前沿、医教研产融合与转化典范的生 命健康之城。此次活动既是临床创新成果的集中亮相，也是成都未来医学城"医教研产"协同发展的生动 展现。作为川渝首个"医疗器械领先用户社区应用示范点"，成都未来医学城锚定"西部医疗器械创新高 地"定位，以"立园满园"行动为引领，正持续完善创新转化保障体系，全力破解医疗器械临床研究成果 转化中"不愿转、不敢转、不会转"的 ...

Trading Activity - The average daily trading amount on the North Exchange increased by 8.83% to 28.738 billion yuan[7] - The weekly turnover rate for the North Exchange was 27.94%[7] - The North Exchange's trading amount accounted for 0.94% of the total market, remaining stable compared to the previous week[11] Index Performance - The North 50 Index declined by 3.59% during the week[16] - Other major indices also experienced declines, with the ChiNext Index down by 0.91% and the Shanghai Composite Index up by 0.10%[16] Sector Analysis - Most sectors on the North Exchange had negative median returns, with the petroleum and petrochemical sector leading with a median increase of 33.99%[21] - The power equipment sector had the largest median decline at -8.07%[21] - The computer industry had the highest median P/E ratio at 139.33 times, indicating high valuation compared to other sectors[21] New Listings - One new stock was offered and two new stocks were listed on the North Exchange during the week[44] - The first-day average price increase for the newly listed stocks was 105.63% for Agricultural University Technology and 186.93% for Meidel[44] New Third Board Trading - The trading scale of the New Third Board decreased, with the innovative tier's trading amount down by 12.08% to 0.965 billion yuan, while the basic tier increased by 22.05% to 0.372 billion yuan[36]

本周医药板块表现弱于整体市场，医药商业降幅居前。本周全部 A 股下 跌 0.98%（总市值加权平均），沪深 300 上涨 0.08%，中小板指下跌 3.78%，创业板指下跌 0.09%，生物医药板块整体下跌 3.31%，生物医 药板块表现弱于整体市场。分子板块来看，化学制药下跌 3.20%，生物 制品下跌 2.50%，医疗服务下跌 4.15%，医疗器械下跌 3.86%，医药商 业下跌 4.49%，中药下跌 1.94%。医药生物市盈率（TTM）37.27x，处 于近 5 年历史估值的 80.47%分位数。 精锋医疗为领先的手术机器人公司。精锋医疗成立于 2017 年，是中国 首家、全球第二家同时取得多孔腔镜、单孔腔镜及自然腔道三类手术机 器人注册审批的领先企业，2024 年斩获国内手术机器人制造商销量第 一，2026 年 1 月于香港联交所挂牌上市。公司核心管理层具备深厚的 行业经验与国际背景，全球专利布局超 734 项，技术实力雄厚。 精锋医疗构建了覆盖多科室的丰富管线。多孔系列 MP1000 及升级款 已获批多专科应用并实现商业化放量，单孔系列 SP1000 为国内首个 覆盖三大外科的国产单孔机器人，支气管 ...

明智科技股份有限公司 据港交所1月30日披露，明智科技股份有限公司(简称：明智科技)向港交所主板递交上市申请，建银国际为 其独家保荐人。招股书显示，明智科技是一家平台型医疗器械公司，凭借创新可视化与微创医疗器械，在 一次性泌尿科内窥镜领域处于领先地位。公司于硅谷及中国营运，专注于一次性内窥镜系统的研发和商业 化。明智科技是全球极少数成功实现一次性内窥镜供应链垂直整合的公司之一，涵盖从核心光电组件及精 密零件的自主研发制造，到完整系统的组装全过程。凭借公司的自有品牌组合-包括OTU(ONETU)、与顶尖 医疗科技公司共同打造的OTU联合品牌，以及 WiScope -- 公司已开发覆盖泌尿科、肝胆外科、呼吸科、耳 鼻喉科、肠胃科及妇科的全面产品组合。 (於開曼群島註冊成立的有限公司) 【繼臺】 [編纂]行使與否而定) WiseTek Med Ltd. 獨家保薦人、[編纂] 「編纂」項下的「編纂」數目 : 「編纂I股股份(視乎[編纂]行使與否而定) 「編纂]數目 「編纂]股股份(可予[編纂]) ·· [編纂]數目 [編纂]股股份(可予[編纂]且視乎 … 0.00565% 聯 交 所 交 易 費 及 0.00015% ...

智通财经APP获悉，据港交所1月30日披露，明智科技股份有限公司(简称：明智科技)向港交所主板递交上 市申请，建银国际为其独家保荐人。招股书显示，明智科技是一家平台型医疗器械公司，凭借创新可视化 与微创医疗器械，在一次性泌尿科内窥镜领域处于领先地位。公司于硅谷及中国营运，专注于一次性内窥 镜系统的研发和商业化。明智科技是全球极少数成功实现一次性内窥镜供应链垂直整合的公司之一，涵盖 从核心光电组件及精密零件的自主研发制造，到完整系统的组装全过程。 凭借公司的自有品牌组合-包括 OTU(ONETU®)、与顶尖医疗科技公司共同打造的OTU联合品牌，以及WiScope®——公司已开发覆盖泌尿 科、肝胆外科、呼吸科、耳鼻喉科、肠胃科及妇科的全面产品组合。 最高[編纂] : 每 股 [ 編 纂 ] 編 纂 ] 港 元,另 加 1.0% 經 紀 佣 金、0.0027% 證 監 會交易 徵 費、 獨家保薦人、[編纂] 「編纂」項下的「編纂」數目 : 「編纂I股股份(視乎[編纂]行使與否而定) 「編纂]數目 : 「編纂]股股份(可予[編纂]) [編纂]數目 [編纂]股股份(可予[編纂]且視乎 … WiseTek Med Ltd ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [4] Core Insights - The surgical robot market is expected to grow significantly, driven by technological innovation, clinical demand, and policy benefits, particularly in China where the penetration rate is projected to increase from 0.7% in 2024 to 3.0% by 2033 [20][29] - Jingfeng Medical is a leading surgical robot company in China, having achieved significant milestones including the first domestic sales ranking in 2024 and a successful listing on the Hong Kong Stock Exchange in January 2026 [1][10] - The company has a robust pipeline of products across multiple specialties, with its multi-port and single-port surgical robots already commercialized and showing strong sales growth [2][34] Summary by Sections Market Performance - The overall pharmaceutical sector underperformed the market, with a decline of 3.31% in the biopharmaceutical sector, while the A-share market saw an average decline of 0.98% [1] - The TTM price-to-earnings ratio for the biopharmaceutical sector stands at 37.27x, which is at the 80.47th percentile of the past five years [1] Company Overview - Jingfeng Medical was established in 2017 and is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [10] - The company has over 734 global patents, showcasing its strong technological capabilities and commitment to innovation [35] Product Pipeline - The company has developed a diverse product line, including the MP1000 multi-port robot and the SP1000 single-port robot, which are approved for various surgical applications [2][10] - The CP1000 bronchoscopic robot is an innovative product aimed at non-invasive diagnosis and treatment of lung diseases, with significant clinical advantages [31][34] Financial Projections - Jingfeng Medical's revenue for the first half of 2025 reached 149 million RMB, a year-on-year increase of 394%, with surgical robot sales accounting for 92.9% of total revenue [34] - The company is expected to continue its growth trajectory with increasing overseas orders and expanding market presence [35] Competitive Landscape - The multi-port surgical robot market is currently dominated by Intuitive Surgical, which holds an 83% market share, while domestic competitors are rapidly emerging [26] - The single-port robot market is still in its early stages, with Jingfeng Medical holding a first-mover advantage in China [28]

Group 1: Company Overview - Yisiwei is a leading domestic company in automotive manufacturing machine vision equipment, holding the largest market share in China [2] - Aide Technology specializes in orthopedic consumables, focusing on the research, production, and sales of medical devices [3] Group 2: Financial Performance - Yisiwei's projected revenues for 2022 to 2024 are 223 million, 355 million, and 392 million yuan, with net profits of 6 million, 61 million, and 86 million yuan respectively [2] - Aide Technology's projected revenues from 2022 to 2025 are 286 million, 262 million, 275 million, and 302 million yuan, with net profits of 93 million, 64 million, 67 million, and 78 million yuan respectively [3] Group 3: Market Position and Growth Potential - Yisiwei's products are widely used by mainstream joint ventures, domestic new forces, and well-known automotive parts companies, indicating strong market penetration [2] - Aide Technology ranks third in the domestic market for spinal vertebroplasty systems and sixth for spinal implant medical devices, showcasing its competitive position [3] Group 4: Upcoming IPO Details - Yisiwei's IPO price is set at 55.95 yuan per share with a price-to-earnings ratio of 90.39, while Aide Technology's IPO price is 7.67 yuan per share with a price-to-earnings ratio of 14.98 [1][3]

Investment Rating - The report suggests a focus on the company, with a recommendation to pay attention to its competitive position in the orthopedic surgical solutions market [4][42]. Core Insights - The company, Aide Technology, specializes in orthopedic consumables and has a projected net profit of 77.75 million yuan for 2025, reflecting a year-on-year increase of 15.82% [4][39]. - The company plans to use the funds raised from its IPO for expanding production capacity, building a research center, and developing a marketing network, which is expected to enhance sales scale and market share [12][14]. - The orthopedic medical device market in China is projected to reach 24.6 billion yuan by 2024, with significant growth in various segments such as spinal implants and trauma devices [42][50]. Company Overview - Aide Technology was established in 2006 and focuses on the research, production, and sales of orthopedic medical devices, including spinal, trauma, and sports medicine products [14][39]. - The company holds 110 patents and has several core products certified by the EU CE authority [14][39]. - The sales model primarily relies on distributors, with the top five customers accounting for 31.87% of total sales in the first half of 2025 [35][36]. Financial Performance - Revenue is projected to grow from 262 million yuan in 2023 to 302 million yuan in 2025, with a compound annual growth rate (CAGR) of 2% from 2022 to 2025 [39]. - The gross margin is expected to decline slightly from 62.45% in 2022 to 58.90% in 2025, while the net profit margin is projected to decrease from 32.70% to 25.85% over the same period [39][41]. Industry Insights - The orthopedic medical device industry is rapidly growing, with the market for orthopedic implants expected to reach 24.6 billion yuan by 2024 [42][50]. - The spinal implant market specifically is projected to grow to 7.2 billion yuan in 2024, despite a temporary decline due to national procurement policies [46][48]. - The trauma implant market is also expected to recover, reaching 3.9 billion yuan in 2024, following a downturn in previous years [52].

Investment Rating - The report does not explicitly state an investment rating for the surgical robot industry, but it indicates a positive outlook for growth and development in the sector. Core Insights - The surgical robot industry in China is entering a rapid development phase, supported by national policies and capital investment, with significant advancements in technology and market demand [13]. - The report highlights the transition from a capital-driven to a value-driven model in the surgical robot sector, emphasizing the importance of clinical applications and technological integration [13]. - The approval process for surgical robots by the NMPA has accelerated, particularly for orthopedic surgical robots, which dominate the market in terms of the number of products approved [30][28]. Summary by Sections Market Overview - The surgical robot market in China is characterized by a growth in sales volume, with a total of 332 units sold in the first 11 months of 2025, reflecting a year-on-year increase of 3.75% [34]. - The sales revenue for surgical robots reached 2.973 billion yuan, showing a slight decline of 0.87% year-on-year, indicating a structural transition rather than a market downturn [34]. Technological Advancements - Innovations in remote operation, miniaturization, and AI assistance are driving the development of surgical robots, with products like the TUMAI® remote surgical robot achieving significant milestones in cross-border surgeries [16][19]. - The introduction of AI-assisted surgical robots is enhancing precision in surgeries, with products capable of 3D reconstruction and personalized surgical planning [16]. Regulatory Developments - The National Healthcare Security Administration has established a pricing framework for surgical robots, which is expected to facilitate market growth by clarifying reimbursement policies and pricing structures [27][26]. - The pricing guidelines categorize surgical robot services into navigation, participation in execution, and precision execution, linking them to main surgical procedures [27]. Market Segmentation - The orthopedic surgical robot segment holds the largest market share, accounting for 50% of the total NMPA-approved surgical robots from 2014 to 2024, followed by neurosurgical robots [30]. - The report indicates a significant potential for growth in emerging fields such as vascular surgery robots, with increasing demand and technological advancements [34]. Competitive Landscape - The report identifies key players in the surgical robot market, including domestic manufacturers that are rapidly gaining market share as regulatory barriers for imports increase [45]. - The competitive landscape is shifting as domestic products receive NMPA approval, challenging the previously dominant imported products [45].

Core Viewpoint - As of January 30, 2026, Gongdong Medical (605369) closed at 18.91 yuan, down 3.77% from the previous week's 19.65 yuan, indicating a decline in stock performance [1] Company Performance - The highest intraday price for Gongdong Medical on January 26 was 19.94 yuan, while the lowest intraday price on January 29 was 18.71 yuan [1] - The current total market capitalization of Gongdong Medical is 4.17 billion yuan, ranking 91 out of 127 in the medical device sector and 3975 out of 5184 in the A-share market [1] Company Announcements - Gongdong Medical announced a change in the signing accountant for the 2025 fiscal year, with Yang Guoqing added as a signing registered accountant [1] - The previous signing accountants were Ning Yifeng and Guo Senhao from Tianjian Accounting Firm, but due to internal adjustments, the change was made [1] - Yang Guoqing has been a certified public accountant since 2015 and has signed or reviewed audit reports for listed companies such as Wansheng Intelligent and Great Wall Technology in the past three years, demonstrating relevant professional capability and independence [1] - The change in accountants is not expected to adversely affect the company's financial statements or internal control audit for the 2025 fiscal year [1]